Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact firstname.lastname@example.org
SOURCE Research and Markets
DUBLIN, October 3, 2017 /PRNewswire/ --
The "Lyophilized Injectable Drugs to 2024" report has been added to Research and Markets' offering.
The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed - a requirement referred to as the cold chain'. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection.
What You Will Learn
Report Value Chain - Who Should Read this Report
Key Topics Covered:
The Market Opportunity
Delivery Market Dynamics
Lyophilized Drugs - Primary Packaging
Lyophilized Drugs - Reconstitution and Delivery
Lyophilized Drugs - Key Therapeutic Sector Analysis and Market Data
For more information about this report visit https://www.researchandmarkets.com/research/qlln28/lyophilized
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
©2017 PR Newswire. All Rights Reserved.